Low back pain: what the evidence says actually helps

Low back pain guidance has converged across health systems in a way that is unusual for musculoskeletal medicine. The UK’s National Institute for Health and Care Excellence (NICE) publishes a national guideline on assessment and management of low back pain and sciatica, known as NG59.^[1] In the United States, the American College of Physicians (ACP) published its own clinical practice guideline on noninvasive treatments for acute, subacute, and chronic low back pain in the Annals of Internal Medicine.^[2] Both guidelines draw on systematic reviews of the trial evidence, including Cochrane reviews on specific treatments, and both apply mainly to non-specific low back pain: pain without a clear structural cause such as a fracture, infection, or nerve compression severe enough to need imaging or referral.

Despite being written for different health systems a continent apart, the two guidelines land on the same broad shape of advice: most people improve without a specific treatment, staying active outperforms rest, exercise and other non-drug approaches come first, and medication is a secondary tool rather than a fix.

NICE recommends against routinely offering imaging in a non-specialist setting for people with low back pain.^[1] That is not because scans are inaccurate. It is because findings such as disc bulges, degeneration, and age-related wear show up on MRI in a large share of people who have no back pain whatsoever, so a scan often cannot tell you whether a given finding explains your symptoms or is simply an incidental feature of a normal spine.

Ordering imaging without a specific reason tends to generate anxiety about an incidental finding and sometimes leads to intervention that would not otherwise have been considered, without improving outcomes. Imaging becomes appropriate when red-flag symptoms suggest a specific cause worth investigating, covered later in this article.

Both guidelines push in the same direction on activity: NICE recommends encouraging people to continue with normal activities as part of managing low back pain, rather than prescribing rest.^[1] This reflects a broader shift in acute-injury care away from strict immobilization and toward earlier, graded movement; our article on how RICE has evolved into frameworks like PEACE & LOVE covers the same theme for acute soft-tissue injury more broadly.

This does not mean pushing through severe pain. Modifying specific movements that clearly aggravate symptoms in the first day or two is reasonable. The distinction is between temporary, sensible modification and extended bed rest, which the evidence behind these guidelines treats as the less helpful default.

For chronic low back pain specifically, exercise has the strongest evidence base of any single intervention. A 2021 Cochrane review pooling dozens of randomized trials found moderate-certainty evidence that exercise therapy is probably effective for reducing pain in chronic low back pain compared with no treatment, usual care, or placebo.^[3] The improvement in day-to-day function was smaller and, on its own, fell short of what the reviewers considered a clinically important difference.

The ACP guideline reaches a compatible conclusion from the other direction: exercise sits among its recommended first-line, non-drug treatments for both acute and chronic low back pain, ahead of any medication.^[2]

Paracetamol. A systematic review and meta-analysis of placebo-controlled trials found high-quality evidence that paracetamol is not effective for reducing pain intensity in people with low back pain.^[4]NICE’s guideline reflects this directly, advising against offering paracetamol alone for managing low back pain.^[1]

NSAIDs. A Cochrane review of NSAIDs for chronic low back pain found a small benefit over placebo (roughly 3 points on a 0 to 100 pain scale and under 1 point on a 0 to 24 disability scale), and rated the certainty of that evidence as low.^[5] NICE allows oral NSAIDs at the lowest effective dose for the shortest duration needed, alongside attention to individual risk factors.^[1] For a closer look at how NSAIDs interact with tissue healing more broadly, see our article on NSAIDs after injury.

Opioids. Both guidelines are notably cautious here. The ACP guideline places opioids last, recommending them only after non-drug treatment and other medications have failed, and only with an explicit discussion of risks and realistic benefits.^[2] NICE takes a similarly restrictive view for ongoing low back pain.^[1]

Alongside exercise, the ACP guideline lists a broader menu of non-drug options: superficial heat, massage, acupuncture, and spinal manipulation for acute pain; and for chronic pain, multidisciplinary rehabilitation, cognitive behavioral therapy, mindfulness-based approaches, and similar programmes alongside exercise.^[2] These are offered as reasonable choices rather than as clearly superior alternatives to exercise, and the evidence quality behind several of them individually is thinner than the evidence for exercise itself.

The common thread across both guidelines is a preference for active, patient-involved approaches over passive treatment delivered in isolation. Passive therapies are generally framed as reasonable additions alongside exercise and self-management, not as replacements for them.

Most low back pain is non-specific and self-limiting, but a smaller set of symptoms warrant prompt medical assessment rather than self-management. These “red flag” patterns are the reason guidelines carve out exceptions to their usual advice against imaging and in favor of staying active.

Outside of these patterns, the guidance covered above applies: staying active, avoiding routine imaging, and treating exercise as the primary long-term intervention.

Low back pain guidance has quietly become one of the more settled areas of musculoskeletal medicine. NICE, the ACP, and the Cochrane reviews behind them agree on the shape of what helps: stay active rather than resting, treat imaging as something reserved for specific concerns rather than a routine first step, and lead with exercise and other non-drug approaches before medication. See how these approaches compare with other recovery-focused interventions we cover in our evidence ratings.

None of this promises a fast fix, and it is not meant to. It reflects what large bodies of trial evidence and guideline development actually support, which is consistently less dramatic, and more durable, than most marketing around back pain treatment suggests.